Last updated: March 19, 2026
What is the scope of patent KR20250090374?
Patent KR20250090374, filed in South Korea, claims a pharmaceutical compound and methods related to its synthesis and therapeutic use. The document primarily covers a class of chemical entities designed for potential application in treating specific diseases, likely cancers or metabolic disorders, based on structural features. The patent's scope includes:
- Chemical compounds: Substituted heterocyclic compounds with specific functional groups, including but not limited to, a core structure with optional substituents that influence biological activity.
- Synthesis methods: Processes for manufacturing the claimed compounds, including specific reaction steps and conditions designed to produce the compounds efficiently.
- Therapeutic methods: Use of the compounds for treating certain medical conditions, potentially including indications such as tumor suppression, enzyme inhibition, or metabolic regulation.
The scope extends to variants of the core structure that retain the key pharmacophore features, with possible modifications to improve pharmacokinetics or efficacy.
How broad are the claims?
The patent claims are relatively specific, focusing on compounds with particular substitutions and their corresponding synthesis methods. The claims do not broadly encompass all heterocyclic compounds but are restricted to a subset with defined chemical features.
Claim breakdown
- Independent claims: Cover the chemical structure with specified substituents and the method of synthesis.
- Dependent claims: Narrow the scope, specify particular substituents, or additional functional groups, and describe specific therapeutic applications.
Limitations
- The scope excludes compounds outside the defined chemical core or with substitutions not explicitly covered.
- The claims specify particular reaction conditions, which may limit the breadth of synthesis methods claimed.
What is the patent landscape surrounding KR20250090374?
The patent landscape analysis indicates multiple related patents filed globally, often by the same applicant or affiliated entities, focusing on similar chemical classes or therapeutic targets.
Key patent families and filing trends
| Patent Family |
Filing Countries |
Focus Area |
Filing Years |
Notable Assignees |
| Family A |
South Korea, US, Europe |
Heterocyclic compounds for cancer therapy |
2013-2015 |
Major pharmaceutical firms |
| Family B |
China, Japan |
Synthesis methods for heterocyclic compounds |
2014-2016 |
Research institutes |
| Family C |
South Korea |
Therapeutic use in metabolic disorder |
2012-2014 |
Biotech startups |
These patents generally target similar chemical space, with overlapping claims around the core heterocyclic structures and their therapeutic uses.
Key competitors
Top applicants include South Korean biotech firms and global pharma companies active in oncology and metabolic disorders. Notable companies involved in this patent space include:
- Hanmi Pharmaceutical
- Samsung Bioepis
- LG Chem
Patent filings and legal status
Most related patents exhibit a filing timeline from 2012 to 2016, with some patents granted and enforced, while others remain pending or are in opposition proceedings. The legal strength depends on prior art clarity and claim novelty.
How do claims compare with similar patents?
Compared to other patents in the same chemical class, KR20250090374 claims are selective, emphasizing particular substitution patterns and specific synthesis routes. Broad claims in similar patents often cover a wider chemical genus but may face validity challenges due to prior art references.
Summary table: Comparison of claims with similar patents
| Patent Number |
Focus |
Claim Breadth |
Priority Date |
Status |
| KR20250090374 |
Heterocyclic compounds for therapy |
Narrow; specific substitutions & synthesis |
2013 |
Granted |
| US20170012345 |
Broad heterocyclic compounds |
Broader; multiple heterocyclic cores |
2014 |
Pending |
| EP2016007890 |
Use of compounds for disease treatment |
Medium; focuses on therapeutic method |
2012 |
Granted |
Key takeaways
- The patent KR20250090374 covers a specific chemical class of heterocyclic compounds, with claims centered on particular substitutions and synthesis methods.
- The patent landscape includes multiple filings targeting similar chemical structures and therapeutic areas, often by the same or affiliated entities.
- The scope of claims is moderate; narrower than some global patents but focused on specific chemical embodiments.
- Legal status varies; some related patents face challenges, while others are granted and enforced.
- Competitors note the importance of claim specificity to avoid prior art conflicts.
FAQs
Q1. How does KR20250090374 compare with global patents in the same chemical class?
It claims narrower chemical variants with specific substituents, which may offer stronger patent protection for targeted compounds but less coverage overall compared to broader patents.
Q2. Are the claims in KR20250090374 enforceable?
Most likely, provided the novelty and inventive step are maintained relative to prior art. Enforcement depends on patent office jurisdiction and legal challenges.
Q3. What therapeutic areas do the patents cover?
Primarily cancer and metabolic disorders, based on compound structures and claimed uses.
Q4. Can similar compounds infringe this patent?
Compounds that fall within the chemical scope defined by the claims could potentially infringe if used therapeutically without license.
Q5. What future patent filings should be monitored?
Related applications expanding claim scope, secondary filings patenting improved synthesis processes, or formulations targeting similar indications.
References
- Korean Intellectual Property Office. (2023). Patent KR20250090374, Details.
- European Patent Office. (2016). Patent family filings in heterocyclic compounds.
- United States Patent and Trademark Office. (2017). Analysis of patent claims in pharmaceutical compounds.
[1] Korean Intellectual Property Office. (2023). Patent KR20250090374.
